In this podcast, 2 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting about preventing melanoma recurrence and reducing cancer disparities.
In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting in breast cancer, lymphoma, multiple myeloma, brain tumors, and von Hippel-Lindau syndrome.
In this post, melanoma survivor Bryant Wieneke reflects on what it was like being diagnosed with advanced disease, how he felt more vulnerable after being diagnosed with a second cancer years later, and how he is supporting his mental health.
The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma.
The ASCO Annual Meeting is being held June 2 to 6. Several notable studies will be presented today. Topics include radiation therapy in rectal cancer, osimertinib for lung cancer, vorasidenib for grade 2 glioma, nivolumab for Hodgkin lymphoma, and mirvetuximab soravtansine for ovarian cancer.
The ASCO Annual Meeting is being held June 2 to 6. A study that will be presented today explores combining immunotherapy and targeted therapy to reduce the risk of death and recurrence for people with advanced ovarian cancer.
The ASCO Annual Meeting is being held June 2 to 6, and here is some of the notable research that will be presented today. Topics include treatment for anemia related to myelodysplastic syndromes, pembrolizumab for advanced cervical cancer, surgery options for early pancreatic cancer, weight loss in breast cancer survivorship, the effect of Medicare expansion on racial disparities, and collaborating across borders to help children with leukemia.
Read about 2 studies from the April 2023 ASCO Plenary Series, which highlights the use of adagrasib to target several solid tumors with a KRAS G12C mutation and the use of toripalimab to treat stage III non-small cell lung cancer before and after surgery.
In this podcast, Dr. Christopher Flowers discusses new research from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition, including new treatments for non-Hodgkin lymphoma and models for predicting early disease progression.
Read research from the December 2022 session of the ASCO Plenary Series, which explores combining immunotherapy for advanced non-small cell lung cancer with high PD-L1.
